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Background: We have addressed whether inter-individual methylation variation in somatic (White Blood Cells: 
WBC) DNA of ovarian cancer patients provides potential for prognostic and/or pharmacoepigenetic 
stratification.  
Patient and Methods: WBC DNA methylation was analysed by bisulphite pyrosequencing at ATM, ESR1, PGR, 
MLH1, BRCA1, SFRP1, SFN, RARB loci and the repetitive element LINE1 in 880 SCOTROC1 trial patients 
(paclitaxel-carboplatin versus docetaxel-carboplatin as primary chemotherapy for stage Ic-IV epithelial ovarian 
cancer).  
Results: We observed no significant associations (p<0.005, after correction for multiple testing) for progression 
free survival (PFS) using test and validation sets. However, we did identify mean SFN methylation associated 
with PFS (HR=1.01 per 1% increase in methylation, q=0.028); particularly in the paclitaxel (HR=1.01, 
q=0.006), but not in the docetaxel arm in stratified analyses. Furthermore, higher methylation within the 
estrogen receptor 1 (ESR1) gene was associated with CA125 response (OR=1.06, q=0.04) and with neuropathy 
(HR=0.95, q=0.002), but only in the paclitaxel arm of the trial.  
Conclusions: This is the first study linking DNA methylation variability in WBC to clinical outcome for any 
tumour type; the data generated on novel prognostic and pharmacoepigenetic DNA methylation biomarkers in 
the circulation now need independent further evaluation. 
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Ovarian cancer is the most lethal gynaecological cancer, having a five year survival rate of only 36% in the UK 
[1]. The most widely used primary treatment is cytoreductive surgery and platinum/taxane chemotherapy. Over 
80% of patients respond to primary chemotherapy, however, the majority relapse within 18 months [2]. The 
factors which underlie variations in outcome are unclear, but are likely to be both tumour and host-related. 
What is clear is that the identification of biological markers of response and survival, measurable at 
presentation, could play a major role in optimising treatment strategies. This becomes increasingly important as 
more molecularly targeted therapies show activity in ovarian cancer, since these will need evaluation within the 
context of platinum/taxane chemotherapy of ovarian cancer.  
The SCOTROC1 phase III randomised clinical trial compared docetaxel-carboplatin to paclitaxel-carboplatin in 
ovarian cancer patients at first presentation [3]. The trial showed no difference in progression-free or overall 
survival between treatment arms, but did show greater levels of neurotoxicity in the paclitaxel arm (30% vs 
11%) and a higher incidence of high grade neutropenia in the docetaxel arm (94% vs 84%). Pharmacogenetic 
studies in the SCOTROC1 cohort have so far identified no significant associations with genotypes in candidate 
genes [4], and have failed to replicate two genome-wide association studies (GWAS) identified survival-
associated SNPs in the phase 3 replication stage of the GWAS [5].  
There is increasing evidence from cancer epidemiological studies that DNA methylation in normal somatic cells 
such as WBCs can be informative about environmental carcinogen exposures and cancer risk [6, 7]. We have 
previously demonstrated that epigenetic variability at candidate loci in peripheral blood DNA may be useful as 
biomarkers of breast cancer risk, and have replicated the risk association of one marker in the ATM gene in pre-
diagnostic blood samples [8, 9]. In the present study, we hypothesise that epigenetic variation detected in non-
Flanagan et al,  Pharmacoepigenetics of ovarian cancer patients - 4 - 
 
cancer somatic cells, white blood cell (WBC) DNA isolated prior to chemotherapy, might also be useful to 
predict clinical outcome following chemotherapy.  
The primary objective of the study was to identify an association between WBC DNA methylation of candidate 
genes (at presentation) and progression-free survival (PFS) in ovarian cancer patients. Secondary objectives 
were to identify an association with overall survival (OS), RECIST response, CA125 response, or toxicity 
(hematological toxicity, GI toxicity and neurotoxicity). Candidate genomic targets were chosen based on known 
methylation variability or a potential role in drug sensitivity including (1) known methylation variable 
intragenic regions across the ataxia-telangiectasia mutated (ATM) gene that had previously been associated with 
breast cancer risk [8, 9] (2) LINE1 repetitive elements as a surrogate for genome-wide methylation levels; (3) 
genes known to be hypermethylated in ovarian cancers estrogen receptor 1 (ESR1), progesterone receptor 
(PGR), breast cancer susceptibility gene 1 (BRCA1), secreted frizzled-related protein 1 (SFRP1), stratifin 
(SFN), retinoic acid receptor beta (RARB) (http://www.pubmeth.org/)  and (4) genes where methylation in 
ovarian tumours is known to associate with drug sensitivity and progression free survival from previous studies, 
mutL homologue 1 (MLH1) [10, 11]. To our knowledge, this is the first such study to systematically investigate 
candidate gene DNA methylation biomarkers in WBC DNA taken at presentation for any cancer type.  
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Materials and Methods 
Patient Samples 
Peripheral blood DNA was available from whole blood from 880 of the 1077 patients enrolled in the 
SCOTROC1 clinical trial which has been described in more detail elsewhere [3, 4]. Patient characteristics of 
samples analysed are summarized in Supplementary Table 1. All patients gave written informed consent for 
blood samples to be collected, and appropriate ethical review boards approved the study. All laboratory 
analyses were conducted blinded to clinical outcomes and the statistical analysis plan was prospectively 
designed following REMARK recommendations [12]. For completeness of reporting, all data are presented in 
Supplementary Table 3. 
 
Laboratory methods 
DNA extracted from whole blood were analysed by bisulphite DNA pyrosequencing using primers described in 
Supplementary Table 2. Any sample failing quality control was removed from the analysis as listed in 
Supplementary Table 4. Full details of the methods are given in Supplementary Methods. 
 
Statistical Analysis  
Following a statistical power analysis to determine the number of samples required for test and validation sets 
unadjusted univariate models were first run. The methylation markers were initially run in the models as 
continuous values, but for methylation markers with markedly skewed distributions (i.e SFRP1, both regions of 
the ATM markers, MLH1, SFN and the second region assayed of ESR1), cubic transformation was used to help 
improve model fit.  Logistic regression models were used to investigate the association between each of the 
markers and CA125 response, response to therapy (progressive disease versus stable disease or complete or 
partial response using RECIST criteria [13], serious hematological toxicity, GI toxicity (three or four grade GI 
toxicity versus zero to two), and neurotoxicity (two to four grade neurotoxicity versus zero or one). All 
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multivariable cox and logistic models were adjusted for figo stage, age, bulk of residual disease, ECOG 
performance status, histological type and platelets to ensure independence from these known prognostic factors. 
Multiple testing was accounted for using Benjamini Hochberg correction.  Data were analyzed by use of R, 
version 2.10. Further details on statistical analysis are reported in Supplementary Methods. 





Association with Progression-Free Survival 
The patients and study design is described in Supplementary Figure 1. The 11 loci tested included four promoter 
CpG islands (CGI) (BRCA1, PGR, RARB and MLH1), and were typically unmethylated with rare examples of 
individuals who were methylated at these promoters (Figure 1). We also assayed six intragenic methylation 
(IGM) regions which were highly methylated and typically more variable than CpG islands (two regions of the 
ESR1 and ATM genes each, SFRP1 and SFN) [14]. Lastly, we also assayed for one repetitive element, LINE1, 
representing genome-wide methylation.  
 
Using mean methylation of the CpG sites, no significant associations with progression free survival in both test 
and validation analyses were found for any locus using the multiple correction p-value cutoffs (p<0.005). We 
did observed four loci that were nominally significant (p<0.05) in the test set, but these were not significant 
after correction for multiple testing and were not significant in the validation set (Table 1). However, a single 
CpG site at SFN identified as nominally significant in the test set, retained nominal significance (p=0.026) with 
a False Discovery Rate (FDR) of q=0.104 in the validation set.  
 
A CpG site in SFN associated with PFS and neurotoxicity 
Mean methylation at the stratifin gene (SFN) locus was associated with PFS (HR=1.03 for every 3% increase in 
methylation, q=0.028) in the full data set (Table 2). Using a dichotomous categorical quantile split on the 
combined dataset (n=712), using the mean SFN methylation, we observed that the three highest quantiles 
(n=534) of methylation had significantly poorer PFS compared to the lowest quantile (n=178) (HR=1.3 (1.1-
1.6), p value=0.01, logrank test p=0.04) resulting in a mean PFS time of 18 months in the lowest quantile of 
methylation compared to 14 months for the remaining individuals. Interestingly, a single CpG site in SFN was 
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associated with PFS (HR=1.01 (1.00, 1.03), p=0.016) and with high grade (2/3/4) neuropathy (OR=1.01 (1.00-
1.04), p=0.029). In the SCOTROC1 trial significantly higher neuropathy was observed in the paclitaxel 
compared to the docetaxel arm [3].  Interestingly, the association between SFN methylation and PFS was only 
significant in the paclitaxel arm (q=0.006) and not the docetaxel arm (q=0.732), with a trend for association 
(q=0.07) with high grade neuropathy in the paclitaxel arm (Table 2).  
 
Methylation at ESR1 associates with response to chemotherapy and neuropathy in the paclitaxel arm. 
A significant association was observed for one region of ESR1 with CA125 response and high grade 
neuropathy. Using a categorical split (above and below the median) higher methylation of ESR1p3a was 
associated with a 2-fold increase in CA125 response (OR= 2.1 (1.4-3.1), p=0.0004). Of note we also observed 
an interaction between ESR1p3a mean methylation and high grade neuropathy, again with a stronger 
association in the paclitaxel arm of the trial (OR= 0.95 for each 1% increase in methylation (0.93-0.98), 
q=0.002, p interaction between study arm and ESR1p3a mean methylation p=0.006) which was not significant 
in the docetaxel arm of the trial (Table 2).  




It is clear that epigenetic alterations, detected in tumour DNA, play an important role in carcinogenesis and drug 
resistance in many tumour types, including ovarian cancer [15]. For instance, variation in tumour DNA 
methylation such as at CpG islands associated with the promoter of WNT pathway genes is independently 
associated with PFS and response to chemotherapy in high grade serous ovarian cancer [16]. Changes in DNA 
methylation in tumour DNA has also been observed during the acquisition of drug resistance in ovarian cancer 
[10, 11]. Thus, there is substantial evidence for DNA methylation and epigenetic regulation in tumours 
influencing sensitivity to platinum-based chemotherapy and patient survival in ovarian cancer.  What is not yet 
clear is whether the normal epigenetic diversity in the population, or epigenetic variation in the normal cell 
DNA of individuals, plays a role in patients’ response to therapy. Recent studies have shown that DNA 
methylation in WBCs can be informative about environmental carcinogen exposures and cancer risk [6, 7], 
although potential prognostic or pharmacoepigenetic relevance of DNA methylation has not been examined. To 
this end, we have performed a pharmacoepigenetic study to systematically investigate candidate gene DNA 
methylation biomarkers in WBC DNA taken at presentation from a phase III ovarian cancer clinical trial, 
SCOTROC1 [3] .  
 
In the SCOTROC1 trial, significantly higher neuropathy was observed in the paclitaxel compared to the 
docetaxel arm, while the docetaxel arm had higher haematological toxicity [3]. Interestingly, the association 
between SFN methylation and PFS we observe, was only significant in the paclitaxel arm and not the docetaxel 
arm. Neurotoxicity was significantly associated with taxane dose reductions during the SCOTROC1 trial 
(OR=3.47, 95% CI=1.99-6.14, p<0.001). This raises the speculation that the associations with PFS and 
neuropathy may be linked and could be a consequence of a systemic effect of methylation on pharmacological 
response to chemotherapy in these patients rather than tumour response per se. We also observe an interaction 
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between ESR1p3a mean methylation and high grade neuropathy, with a stronger association in the paclitaxel 
arm of the trial.  
 
Stratifin (SFN, 14-3-3 sigma) is a member of the 14-3-3 family that interacts with p53, to initiate cell cycle 
checkpoints after DNA damage [17]. In a small study of neuroblastomas (n=47 (test); n=58 (validation)), 
hypermethylation of the SFN promoter in tumour DNA was associated with poorer progression-free and overall 
survival [18]. However, in our study we have not examined methylation of the promoter region, but rather an 
intragenic CpG site previously demonstrated to show DNA methylation variability between individuals [8]. 
That a single CpG site can be important for patient survival was recently demonstrated in chronic lymphocytic 
leukemia [19].  
 
A link between estrogen and ovarian cancer risk has long been suspected and recent, large case-control studies 
have shown an increased risk of ovarian cancer mortality associated with HRT use [20]. The mechanism of this 
increased mortality is not known, however, ESR1 expression in tumours is lower in patients with poorer 
survival [21] and CA125 response [22]. High levels of estrogen inhibit paclitaxel induced apoptosis in cancer 
cells lines and inhibits paclitaxel efficacy in mouse xenograft ER positive tumours [23, 24]. We hypothesise, 
therefore, that high levels of ESR1 methylation observed in blood DNA may be protective against paclitaxel 
related neurotoxicity due to higher ESR1 expression and more interference with paclitaxel induced apoptosis. 
The limitations of this study include the small effect sizes observed when methylation is analysed as a 
continuous measure.  However, these must be interpreted within their context: hazard ratios are represented per 
1% increase in methylation or per 1 Standard deviation and so may appear small but may still represent large 
increases in risk. It is also important to note that the distribution of methylation for markers (presented in Figure 
1), shows that most of the markers we have investigated have methylation ranges of 20-30% between 
individuals which does have a significant impact on gene expression as we have shown for the ATM markers 
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[8]. A further limitation is epithelial ovarian cancer is now considered to consist of at least 5 different subtypes 
of ovarian cancer, with different molecular pathology and clinical outcome [25]. SCOTROC1 included all 
histological subtypes of epithelial ovarian cancer, and the methylation differences we observe could reflect 
association with particular subtypes with distinct clinical outcomes. We avoided further subgroup analysis 
based on histological subtype as this would further reduce the statistical power of the analysis. However, the 
analyses presented were adjusted for histological type (serous versus non-serous) and it is unlikely that the 
toxicity associations would be due to histological subtype of ovarian cancer. Since this study was done within 
patients selected for eligibility for recruitment to the SCOTROC 1 clinical trial it is possible that there is 
restricted generalisability to a non-selected ovarian cancer population.    
 
Whole blood DNA is a mixture of numerous different cell types that may have differential methylation at the 
candidate gene loci assessed in this study. However, we have previously shown that the intragenic ATM 
markers tested here are not differentially methylated in B-cells, T-cells or monocytes [8], and recent data of 
blood cell fractions interrogated on the 27K Illumina showed no differential methylation for the gene loci 
represented on the array (BRCA1, MLH1, RARB, PGR) [26].  Furthermore, there was no significant correlation 
between blood counts at time of methylation analysis (WBC, haemoglobin, neutrophils and platelets) and 
methylation of SFN, ESR1 and RARB (data not shown).  
 
In conclusion, we have shown for the first time that analysis of DNA methylation of white blood cells, may 
identify markers of clinical outcome and toxicity in ovarian cancer patients. DNA methylation status associating 
with markers of toxicity, which if validated in further independent clinical studies, may identify those patients at 
risk of toxicity to paclitaxel or docetaxel. Such markers could be considered for patient stratification in future 
trials involving paclitaxel-carboplatin, which would enrich for patients having the best prospects for longer PFS 
and least toxicity.  
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Figure 1.  
 
Methylation distributions of 11 gene regions shown as box and whisker plots representing median (centre line), 
interquartile range (box), and 95th percentiles (whisker), and samples outside this range are represented as 
points. Each locus is labelled as IGM (intragenic DNA methylation locus), CGI (promoter CpG Island) or Rep 
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Test Validation Full data
Gene Outcome CG site SD Transform N
























SFN PFS 1 2.8 Cubic 429 1.03 1.01 (0.99, 1.03) 0.048 0.549 283 1.04 1.01 (1.00, 1.03) 0.026 0.104 712 1.03 1.01 (1.00, 1.03) 0.016 0.028
SFN PFS Mean 3 Cubic 429 1.03 1.01 (1.00, 1.03) 0.040 0.440 283 1.03 1.01 (0.99, 1.03) 0.231 0.462 712 1.03 1.01 (1.00, 1.03) 0.016 0.028
LINE1 PFS 3 1.9 None 429 1.14 1.04 (1.01, 1.08) 0.019 0.430 220 0.98 0.99 (0.91, 1.08) 0.844 0.844 649 1.11 1.04 (1.01, 1.07) 0.021 0.028
RARB PFS 5 2.2 None 420 1.13 1.12 (1.02, 1.23) 0.018 0.425 255 1.03 1.02 (0.95, 1.08) 0.649 0.844 675 1.09 1.05 (1.00, 1.09) 0.041 0.041  
^Benjamini Hochberg  correction was used for multiple comparisons 
±All models were adjusted for figo stage, age, bulk of residual disease, ECOG performance status, histological type and plate 
Abbreviations: NA= Not applicable 
Note: Survival models were run using cox proportional hazard models and logistic models were run using generalized linear models specifying the 
biniomial family 
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Table 2. Interactions between the two arms of the trial. 
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Table 2. Interactions between the two arms of the trial. 











Arm A - Paclitaxel/Carbo SFN PFS* 1 Cubic 2.9 364 1.03 1.01 (1.00, 1.03) 0.0325 0.0325 0.720
Arm B - Docetaxel/Carbo 1 2.9 348 1.03 1.01 (0.99, 1.03) 0.1856 0.3712
Arm A - Paclitaxel/Carbo Mean 3.0 364 1.04 1.01 (1, 1.03) 0.0029 0.0058 0.080
Arm B - Docetaxel/Carbo Mean 3.0 348 1.02 1.01 (0.99, 1.03) 0.7323 0.7323
Arm A - Paclitaxel/Carbo SFN NeuroTox 1 Cubic 2.9 364 1.04 1.01 (0.99, 1.04) 0.0526 0.0658 0.420
Arm B - Docetaxel/Carbo 1 2.9 348 1.03 1.01 (0.98, 1.04) 0.6287 0.8160
Arm A - Paclitaxel/Carbo Mean 3.0 364 1.03 1.01 (0.99, 1.03) 0.4432 0.4432 0.520
Arm B - Docetaxel/Carbo Mean 3.0 348 0.98 0.99 (0.97, 1.02) 0.8160 0.8160
Arm A - Paclitaxel/Carbo ESR1 CA125 1 None 10.3 220 1.39 1.03 (0.99, 1.08) 0.1493 0.1493 0.796
Arm B - Docetaxel/Carbo 1 10.8 209 1.53 1.04 (1, 1.09) 0.0725 0.2090
Arm A - Paclitaxel/Carbo 2 10.3 219 1.91 1.06 (1.01, 1.12) 0.0143 0.0429 0.711
Arm B - Docetaxel/Carbo 2 10.8 209 1.40 1.03 (0.99, 1.08) 0.1417 0.2090
Arm A - Paclitaxel/Carbo Mean 9.6 404 1.42 1.04 (1, 1.07) 0.0447 0.0671 0.675
Arm B - Docetaxel/Carbo Mean 9.6 385 1.21 1.02 (0.99, 1.05) 0.2090 0.2090
Arm A - Paclitaxel/Carbo ESR1 NeuroTox 1 None 10.3 220 0.62 0.95 (0.92, 0.99) 0.0046 0.0077 0.085
Arm B - Docetaxel/Carbo 1 10.8 209 1.11 1.01 (0.97, 1.05) 0.6142 0.8160
Arm A - Paclitaxel/Carbo 2 10.3 219 0.56 0.94 (0.91, 0.98) 0.0010 0.0025 0.127
Arm B - Docetaxel/Carbo 2 10.8 209 0.93 0.99 (0.96, 1.03) 0.7506 0.8160
Arm A - Paclitaxel/Carbo Mean 9.6 404 0.63 0.95 (0.93, 0.98) 0.0004 0.0020 0.006
Arm B - Docetaxel/Carbo Mean 9.6 385 1.13 1.01 (0.98, 1.04) 0.4315 0.8160  
^Benjamini Hochberg  correction was used for multiple comparisons 
±All models were adjusted for figo stage, age, bulk of residual disease, ECOG performance status, histological type and plate 
Abbreviations: NA= Not applicable 
Note: Survival models were run using cox proportional hazard models and logistic models were run using generalized linear models specifying the 
biniomial family 
 




Supplementary Figure 1.  
 
Study Design for Pharmacoepigenetic analysis of Survival and Toxicity in the SCOTROC1 phase III ovarian 
cancer clinical trial.  
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Supplementary Table 1: Patient characteristics 
Supplementary Table 2: Primers used in this study 
Supplementary Table 3: Full Data set by Continuous variable methylation (All outcomes) 
Supplementary Table 4: Numbers of samples 
 
 
 
